image
Healthcare - Biotechnology - NASDAQ - US
$ 20.23
-6.82 %
$ 1.8 B
Market Cap
-7.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one TVTX stock under the worst case scenario is HIDDEN Compared to the current market price of 20.2 USD, Travere Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one TVTX stock under the base case scenario is HIDDEN Compared to the current market price of 20.2 USD, Travere Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one TVTX stock under the best case scenario is HIDDEN Compared to the current market price of 20.2 USD, Travere Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TVTX

image
$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
233 M REVENUE
60.55%
-321 M OPERATING INCOME
14.89%
-321 M NET INCOME
14.80%
-237 M OPERATING CASH FLOW
15.19%
99.3 M INVESTING CASH FLOW
78.08%
139 M FINANCING CASH FLOW
-36.26%
81.7 M REVENUE
9.29%
-41.2 M OPERATING INCOME
32.12%
-41.2 M NET INCOME
31.60%
-42.2 M OPERATING CASH FLOW
-18.12%
41.3 M INVESTING CASH FLOW
151.41%
3.72 M FINANCING CASH FLOW
-97.33%
Balance Sheet Travere Therapeutics, Inc.
image
Current Assets 417 M
Cash & Short-Term Investments 371 M
Receivables 27.1 M
Other Current Assets 18.9 M
Non-Current Assets 177 M
Long-Term Investments 0
PP&E 19.6 M
Other Non-Current Assets 158 M
62.39 %4.56 %3.18 %3.30 %26.56 %Total Assets$594.1m
Current Liabilities 201 M
Accounts Payable 23.5 M
Short-Term Debt 74.1 M
Other Current Liabilities 103 M
Non-Current Liabilities 334 M
Long-Term Debt 310 M
Other Non-Current Liabilities 24 M
4.40 %13.85 %19.28 %58.00 %4.48 %Total Liabilities$535.0m
EFFICIENCY
Earnings Waterfall Travere Therapeutics, Inc.
image
Revenue 233 M
Cost Of Revenue 7.74 M
Gross Profit 225 M
Operating Expenses 557 M
Operating Income -321 M
Other Expenses 0
Net Income -321 M
300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)233m(8m)225m(557m)(321m)0(321m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
96.68% GROSS MARGIN
96.68%
-137.51% OPERATING MARGIN
-137.51%
-137.90% NET MARGIN
-137.90%
-544.28% ROE
-544.28%
-54.12% ROA
-54.12%
-68.62% ROIC
-68.62%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Travere Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -321 M
Depreciation & Amortization 43.6 M
Capital Expenditures -101 M
Stock-Based Compensation 36.9 M
Change in Working Capital 0
Others 2.69 M
Free Cash Flow -339 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Travere Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for TVTX of $22.2 , with forecasts ranging from a low of $12 to a high of $33 .
TVTX Lowest Price Target Wall Street Target
12 USD -40.68%
TVTX Average Price Target Wall Street Target
22.2 USD 9.99%
TVTX Highest Price Target Wall Street Target
33 USD 63.12%
Price
Max Price Target
Min Price Target
Average Price Target
35353030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Travere Therapeutics, Inc.
image
Sold
0-3 MONTHS
645 K USD 5
3-6 MONTHS
4.58 M USD 8
6-9 MONTHS
1.59 M USD 8
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Travere Therapeutics to Participate at Upcoming Investor Conferences SAN DIEGO--(BUSINESS WIRE)-- #Inrareforlife--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2025 Healthcare Conference Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT Jefferies Global Healthcare Conference Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET Scotiabank Third Annual Healthcare Canadian Investor Day Tuesday, June 17, 2025 Live webcasts of the BofA Securities 2025 Healthcare. businesswire.com - 1 week ago
Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Tyler Van Buren - TD Cowen Vamil Davin - Guggenheim Anupam Rama - JPMorgan Laura Chico - Wedbush Securities Liisa Bayko - Evercore Greg Harrison - Scotiabank Maury Raycroft - Jefferies Prakhar Agrawal - Cantor Jason Zemansky - Bank of America Operator Good afternoon, and welcome to the Travere Therapeutics First Quarter and Full Year 2025 Financial Results Conference Call. Today's call is being recorded. seekingalpha.com - 2 weeks ago
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 2 weeks ago
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates Travere Therapeutics (TVTX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $1.76 per share a year ago. zacks.com - 2 weeks ago
Travere Therapeutics Reports First Quarter 2025 Financial Results SAN DIEGO--(BUSINESS WIRE)-- #1Q25earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update. “As the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, FILSPARI is elevating the standard of care in IgAN. Our strong start to the year reflects this leadership – in the first quarter, we delivered 13% sequential net sales growth for FILSPARI in the U.S., driven by sustained d. businesswire.com - 2 weeks ago
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard MA is granted for all member states of the Euro. businesswire.com - 3 weeks ago
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy European Commission converts conditional approval of FILSPARI (sparsentan)  into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation from Committee for Medicinal Products for Human Use (CHMP) from February 2025 EU approval is based on the complete data set from the phase-III PROTECT study ST. GALLEN, Switzerland and SAN DIEGO , April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). prnewswire.com - 3 weeks ago
Travere Therapeutics to Report First Quarter 2025 Financial Results SAN DIEGO--(BUSINESS WIRE)-- #1Q25Earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Fo. businesswire.com - 3 weeks ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 31,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as. businesswire.com - 1 month ago
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS. businesswire.com - 1 month ago
Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles The stock market is attempting to rebound amid President Donald Trump's trade war. The post Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles appeared first on Investor's Business Daily. investors.com - 1 month ago
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amendment to the REMS sNDA currently under review for modification of liver monitoring SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced the Company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The submission is supported by results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study, two of the largest head-to-head interventional studies conducted to date in adult and pediatric patients with FSGS. globenewswire.com - 2 months ago
8. Profile Summary

Travere Therapeutics, Inc. TVTX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.8 B
Dividend Yield 0.00%
Description Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Contact 3611 Valley Centre Drive, San Diego, CA, 92130 https://www.travere.com
IPO Date Nov. 8, 2012
Employees 385
Officers Dr. Eric M. Dube Ph.D. President, Chief Executive Officer & Director Dr. William E. Rote Ph.D. Chief Research Officer Ms. Elizabeth E. Reed J.D. Chief Legal Officer, General Counsel & Secretary Mr. Casey Logan Chief Business Officer Mr. Peter Heerma Chief Commercial Officer Ms. Angela Giannantonio Chief People Officer Mr. Christopher Cline C.F.A. Chief Financial Officer Dr. Jula Inrig M.D. Chief Medical Officer Ms. Sandra Calvin SVice President, Corporate Controller & Chief Accounting Officer Ms. Nivi Nehra Vice President of Corporate Communications & Investor Relations